Context Therapeutics Completes $25M IPO

Context Therapeutics, Inc., a women's oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, completed its $25 million initial public offering (IPO) of 5,000,000 shares of common stock at public offering price of $5 per share. The common stock began trading on The Nasdaq Capital Market on October 19, 2021 under the ticker symbol CNTX. ThinkEquity LLC acted as the underwriter for the offering. Faegre Drinker represented Context Therapeutics in the transaction.